SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-058225
Filing Date
2020-12-23
Accepted
2020-12-23 16:16:36
Documents
6
Period of Report
2020-12-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20201221.htm 8-K 54773
2 EX-10.1 abio-ex101_6.htm EX-10.1 94569
3 EX-10.2 abio-ex102_11.htm EX-10.2 99867
4 EX-10.3 abio-ex103_7.htm EX-10.3 96687
5 EX-10.4 abio-ex104_8.htm EX-10.4 67158
6 EX-10.5 abio-ex105_9.htm EX-10.5 71549
  Complete submission text file 0001564590-20-058225.txt   486033
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 201412431
SIC: 2835 In Vitro & In Vivo Diagnostic Substances